Volume 3.20 | Jun 1

Prostate Cell News 3.20 June 1, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter

Splice Variant PRKC-ζ-PrC Is a Novel Biomarker of Human Prostate Cancer
To understand the relationship between the structure and biological activities of the gene protein kinase C-zeta (PRKCZ), researchers analyzed its expressed sequence in prostate cancer cell lines and tissues. [Brit J Cancer ] Abstract | Press Release

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)

PUBLICATIONS (Ranked by impact factor of the journal)


Inhibition Kinetics and Regulation of Sphingosine Kinase 1 Expression in Prostate Cancer Cells: Functional Differences between Sphingosine Kinase 1a and 1b

Scientists demonstrated that 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole, FTY720, and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 activity with distinct kinetics, indicating that these compounds exhibit different binding modalities with sphingosine kinase 1. [Int J Biochem Cell Biol] Abstract

Cyclosporin A Suppresses Prostate Cancer Cell Growth through Ca2+/Calmodulin-Dependent Protein Kinase Kinase β/AMPK-Mediated Inhibition of mTOR Complex 1 Signaling
Researchers showed that AMP-activated protein kinase (AMPK) mediates the antitumor effect of cyclosporin A on prostate cancer cells. [Biochem Pharmacol] Abstract

The Use of LC-MS to Identify Differentially Expressed Proteins in Docetaxel-Resistant Prostate Cancer Cell Lines
To identify proteins altered in the docetaxel-resistant phenotype, three parental cell lines DU145, 22RV1 and PC-3, as well as their docetaxel resistant sub-lines, were subjected to quantitative label-free LC-MS proteomic profiling. [Proteomics] Abstract

Sulforaphane, a Cruciferous Vegetable-Derived Isothiocyanate, Inhibits Protein Synthesis in Human Prostate Cancer Cells
Scientists showed that sulforaphane inhibits protein synthesis in PC-3 cells in a dose- and time-dependent manner which is accompanied by a decreased phosphorylation of mTOR substrates. [Biochim Biophys Acta] Abstract

Combined Immunotherapy with Listeria monocytogenes-Based PSA Vaccine and Radiation Therapy Leads to a Therapeutic Response in a Murine Model of Prostate Cancer
Investigators evaluated the combination of radiation therapy and immunotherapy using L. monocytogenes-based vaccine in a mouse model of prostate cancer. [Cancer Immunol Immunother] Abstract

Constitutively Active c-Met Kinase in PC-3 Cells Is Autocrine-Independent and Can Be Blocked by the Met Kinase Inhibitor BMS-777607
Scientists examined the response of PC-3 cells to an anti-hepatocyte growth factor neutralizing antibody or a small molecule Met kinase inhibitor (BMS-777607). [BMC Cancer] Abstract | Full Article

Identification of a Potential Tumor Differentiation Factor Receptor Candidate in Prostate Cancer Cells
Scientists investigated whether tumor differentiation factor receptor candidates from prostate cancer cells are the same as those identified in breast cancer cells. [FEBS J] Abstract | Press Release

Human Bone Marrow-Derived Mesenchymal Stem Cells Produced TGFbeta Contributes to Progression and Metastasis of Prostate Cancer
Researchers observed that human mesenchymal stem cells promoted human prostate cancer cell PC-3 growth in vivo and in vitro. [Cancer Invest] Abstract


Responder Analysis of the Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Men with nonmetastatic prostate cancer receiving androgen deprivation therapy were treated with subcutaneous denosumab 60 mg or placebo every six months for up to 36 months in a phase III, randomized, double-blind study. [Prostate Cancer Prostatic Dis] Abstract

A Randomized Trial of Robotic and Open Prostatectomy in Men with Localized Prostate Cancer
Researchers present the design of a randomized trial of robotic and open prostatectomy for men newly diagnosed with localized prostate cancer. [BMC Cancer] Abstract | Full Article

[New Webinar] Discover How to Reduce Variability in Primary Neuron Cultures with NeuroCult SM


Medivation and Astellas Announce Initiation of Expanded Access Program for Enzalutamide in the United States
Medivation, Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) agreed that Medivation and Astellas may proceed with an expanded access program for the investigational therapy enzalutamide under a treatment protocol in the U.S. while marketing approval is being sought from the FDA. [Medivation, Inc.] Press Release

Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men with Advanced Prostate Cancer
Exelixis, Inc. announced the initiation of COMET-1, a phase III pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer. [Exelixis, Inc.] Press Release

IRIS International Unveils NADiA® ProsVue™ at the American Urological Association (AUA) Annual Meeting
IRIS International, Inc. announced that the Iris Personalized Medicine group is unveiling its novel prostate cancer system, NADiA® ProsVue™ at the AUA Annual Meeting in Atlanta. [IRIS International, Inc.]
Press Release


White House Petitioned to Make Research Free to Access
More than 17,000 people have signed an online petition urging US President Barack Obama to require all scientific journal articles resulting from US taxpayer-funded research to be made freely available online. [White House, United States] Press Release

Horizon 2020: A €80 Billion Battlefield for Open Access
As negotiations proceed to shape the next installment of Europe’s gargantuan research funding programs, scientists, librarians, and publishers are eagerly awaiting the answer to a critical question: How strong will the new seven-year program, called Horizon 2020, be on Open Access? [European Commission, European Union] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 8th Annual World Stem Cell Summit
December 3-5, 2012
West Palm Beach, United States

Visit our events page to see a complete list of events in the prostate cell community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Associate Research Scientist (Columbia University Medical Center)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Fellow – Prostate Research (Baylor College of Medicine)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us